Literature DB >> 32369282

A Trial of Lopinavir-Ritonavir in Covid-19.

Kurt M Kunz1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32369282     DOI： 10.1056/NEJMc2008043

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

Review 1.  Dissecting the interaction between COVID-19 and diabetes mellitus.

Authors:  Ying Jie Chee; Seng Kiong Tan; Ester Yeoh
Journal:  J Diabetes Investig       Date:  2020-08-05       Impact factor: 4.232

Review 2.  An integrative look at SARS‑CoV‑2 (Review).

Authors:  Miguel A Ortega; Oscar Fraile-Martínez; Melchor Álvarez-Mon; Ángel Asúnsolo; Basilio De la Torre; Cielo García-Montero; Sandra García-Gallego; Lara Sánchez-Trujillo; Diego Torres-Carranza; Miguel Ángel Álvarez-Mon; Leonel Pekarek; Natalio García-Honduvilla; Julia Bujan
Journal:  Int J Mol Med       Date:  2020-12-22       Impact factor: 4.101

Review 3.  A Review of Treatment of Coronavirus Disease 2019 (COVID-19): Therapeutic Repurposing and Unmet Clinical Needs.

Authors:  Po-Lin Chen; Nan-Yao Lee; Cong-Tat Cia; Wen-Chien Ko; Po-Ren Hsueh
Journal:  Front Pharmacol       Date:  2020-11-17       Impact factor: 5.810

4.  COVID-19: High-JAKing of the Inflammatory "Flight" by Ruxolitinib to Avoid the Cytokine Storm.

Authors:  Cirino Botta; Alessia Indrieri; Eugenio Garofalo; Flavia Biamonte; Andrea Bruni; Pino Pasqua; Francesco Cesario; Francesco Saverio Costanzo; Federico Longhini; Francesco Mendicino
Journal:  Front Oncol       Date:  2021-01-08       Impact factor: 6.244

5.  Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients.

Authors:  Jean Claude Alvarez; Pierre Moine; Benjamin Davido; Isabelle Etting; Djillali Annane; Islam Amine Larabi; Nicolas Simon
Journal:  Eur J Clin Pharmacol       Date:  2020-10-13       Impact factor: 2.953
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.